We have some exciting news to share! The Motley Fool UK has now become The Twelfth Magpie -- an independent, UK-owned company, led by our long-serving UK management team — Mark Rogers, Chris Nials and Heather Adlington. In practical terms, it’s the same team you know, now fully focused on serving our UK readers and members.

Just as importantly, our approach remains unchanged: long-term, jargon-free, and on your side. This site is our new home, and there will be extra tweaks made across the coming few days as we settle in. So if anything looks a little off, please bear with us!

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Your Ultimate FTSE 100 4-Stock Balanced Portfolio: SSE PLC, AstraZeneca plc, Banco Santander SA & Unilever plc

SSE PLC (LON:SSE), AstraZeneca plc (LON:AZN), Banco Santander SA (LON:BNC) and Unilever plc (LON:ULVR) provide a potent mix of income and capital growth potential.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

city

Sometimes it’s tough to strike the right balance between growth and income. Indeed, most investors tend to focus on one or the other, as opposed to creating a portfolio that provides them with a decent income while also having the potential to post impressive capital gains.

XXX

With that in mind, here are four stocks that, together, offer impressive dividends as well as exciting future prospects.

SSE

As far as income plays go, few stocks in the FTSE 100 can match SSE (LSE: SSE). That’s because it currently yields a hugely impressive 6% and, better still, dividends per share are all set to rise by at least the inflation rate over the medium term.

This may not sound like such an appealing option when inflation is less than 2%. However, with the scale of quantitative easing having the potential to push the inflation rate much higher over the medium term, SSE’s planned dividend increases could become a real asset. Indeed, they could help to maintain your income levels in real terms moving forward.

AstraZeneca

While also offering a respectable yield of 3.6%, AstraZeneca (LSE: AZN) comes with huge capital growth potential. That’s because its drugs pipeline is undergoing nothing short of a transformation right now.

Certainly, the company’s bottom line is due to be hit by continued fallout from the current patent cliff, with earnings forecast to fall by 13% this year and by 6% next year. However, looking beyond that, numerous acquisitions have made AstraZeneca’s pipeline a hot ticket. Indeed, further bids from global rivals are a very real possibility, which would clearly be good news for shareholders.

Banco Santander

Few companies offer the potent mix of income and growth that Santander (LSE: BNC) does. It currently yields a whopping 7.4% and offers huge growth potential. For instance, earnings per share (EPS) are due to increase by 23% in the current year and by 21% next year. This is well ahead of the market average and shows that Santander is a true growth play.

Of course, investors are being asked to pay a premium for such strong growth potential, with shares in Santander currently trading on a price to earnings (P/E) ratio of 15.6. This is much higher than the FTSE 100’s P/E of 13.8. However, when Santander’s growth forecasts are taken into account, it equates to a price to earnings growth (PEG) ratio of just 0.6, which shows that for the level of growth on offer, Santander trades at a reasonable price.

Unilever

With a yield of 3.3% and forecast growth in earnings of 9% next year, Unilever (LSE: ULVR) seems to strike the right balance between growth and income. Indeed, the consumer goods play seems to have a very bright future ahead of it.

For instance, customer loyalty in its brands is constantly increasing in the developing world, where Unilever has invested vast amounts of time and money to ensure the long term growth of its products. This exposure (emerging markets account for over half of Unilever’s revenue) could prove to be highly beneficial for investors moving forward, as greater wealth and consumer spending are anticipated across the developing world. As a result, shares in the company could deliver impressive gains over the medium term.

Peter Stephens owns shares of AstraZeneca and SSE. The Motley Fool UK owns shares of Unilever. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Friends and sisters exploring the outdoors together in Cornwall. They are standing with their arms around each other at the coast.
Investing Articles

£503 buys 14 shares in this FTSE 250 stock that returned 23.9% annually for the last 15 years

This FTSE 250 stock has averaged a huge return for 15 years. At today's price, £503 buys 14 shares. But…

Read more »

Black woman using loudspeaker to be heard
Investing Articles

£1,000 buys 25 shares in this FTSE 100 stock that’s returned 29.2% annually for the last 10 years

This FTSE 100 mining stock has returned close to 30% a year for a decade. At 3,995p, £1,000 buys 25…

Read more »

Female student sitting at the steps and using laptop
Investing Articles

Down 47%, is this growth stock finally worth buying in May?

With a £288m order book and a hidden pipeline of defence and nuclear contracts, is this growth stock now too…

Read more »

House models and one with REIT - standing for real estate investment trust - written on it.
Investing Articles

2 REITs yielding 7%+ to consider for passive income in 2026

A REIT backed by the NHS and another backed by Tesco and Sainsbury's with both yielding 7%+. Here's why I'm…

Read more »

Woman riding her old fashioned bicycle along the Beach Esplanade at Aberdeen, Scotland.
Investing Articles

Just 97 shares of this UK dividend stock generate £238 in passive income

A 5.7% yield, £238 in passive income from just 97 shares, and one of the most divisive dividend stocks on…

Read more »

ISA coins
Investing Articles

£10,000 in an ISA generates a second income of…

The London Stock Exchange is home to some of the world's most generous dividends. But how big a second income…

Read more »

Shot of a senior man drinking coffee and looking thoughtfully out of a window
Investing Articles

Expert recommendations: 2 top income stocks yielding 7%+!

With yields of 7.2% and 7.8% respectively, these two income stocks are catching the eyes of institutional analysts. Should investors…

Read more »

Illustration of flames over a black background
Investing Articles

3 top income-focused stocks to buy in May 2026, according to experts

Looking for a stock to buy for income in May 2026? Experts have flagged these three UK dividend shares as…

Read more »